StocksMedium•9 November 2026•
1 min read
Heron Therapeutics Q3 Revenue Misses Estimates Despite Meeting EPS Target
Key Facts
1Heron Therapeutics reported Q3 revenue of $35.25 million, missing estimates of $38.25 million.
2The company reported earnings of -$0.03 per share, meeting analyst estimates.
Heron Therapeutics reported Q3 2026 revenue of $35.25 million, missing analyst estimates of $38.25 million. According to Quiver Quantitative, the company reported a loss of $0.03 per share, which was exactly in line with market expectations for the fiscal period ending September 2026.
HRTX closed at $0.293 on November 6, 2026, prior to the release of the financial results that showed a revenue miss of approximately 8% against estimates. The stock traded between a low of $0.2766 and a high of $0.2958 during the November 6, 2026 session.